腋股动脉旁路术治疗间歇性跛行的结局
基于血管质量倡议(2009-2019)数据,比较436例腋股动脉旁路术(AxFB)与2825例主股动脉旁路术(AoFB)治疗间歇性跛行的围术期和1年结局。AxFB患者合并症更多,围术期肺部及肾脏并发症更少但同侧大截肢更多,1年死亡、移植物闭塞或死亡、再干预/截肢/死亡风险更高;多变量分析显示AxFB与1年再干预、截肢或死亡风险独立相关(HR 1.6)。作者认为使用AxFB治疗间歇性跛行前应慎重考虑。
要点
- AxFB患者较AoFB患者年龄更大、合并症更多,围术期肺部(3% vs 7.9%)和肾脏(5.5% vs 9.9%)并发症更少,但同侧大截肢更多(0.9% vs 0.04%)。
- 1年时AxFB较AoFB死亡(7.3% vs 3.6%)、移植物闭塞或死亡(14.3% vs 7.2%)、同侧大截肢或死亡(12.5% vs 5.6%)、再干预/截肢/死亡(19% vs 8.6%)均更高。
- 多变量分析显示AxFB与1年再干预、截肢或死亡风险独立相关(HR 1.6,95%CI 1.03-2.4,P=0.04)。
核心结论
- 回顾性分析结果提示,接受AxFB的患者较AoFB患者长期并发症更常见,尽管AxFB患者风险更高且合并症更多。
- 由于AxFB与显著的围术期并发症、死亡和长期并发症相关,作者认为在用于治疗间歇性跛行前应慎重考虑。
研究设计与样本
- 回顾性分析血管质量倡议(2009-2019)中因间歇性跛行行腹股沟上旁路术的患者,比较AxFB与AoFB的围术期和1年结局。
- 共纳入3261例腹股沟上旁路术,其中AxFB 436例,AoFB 2825例;采用单变量和多变量分析。
主要发现
- 平均年龄61.4±9.1岁,男性占58.8%,目前吸烟者占59.7%。
- AxFB患者较AoFB患者更常年龄更大、男性、从不吸烟和辅助行走(P<0.001);更常合并高血压、糖尿病、冠心病、充血性心力衰竭、慢性阻塞性肺疾病和终末期肾病,以及既往外周流出道腔内介入和既往流入道或流出道旁路术;AxFB较AoFB更常为单股动脉(P<0.05)。
- AxFB较AoFB术后住院时间更短(中位4天 vs 6天),围术期肺部并发症(3% vs 7.9%)和肾脏并发症(5.5% vs 9.9%)更少,但围术期同侧大截肢更多(0.9% vs 0.04%;P<0.05)。
- 围术期心肌梗死(2.8% vs 2.7%)、卒中(0.7% vs 1.1%)和死亡(1.8% vs 1.7%)无显著差异。
- 1年Kaplan-Meier分析显示,AxFB较AoFB死亡(7.3% vs 3.6%;P=0.002)、移植物闭塞或死亡(14.3% vs 7.2%;P=0.001)、同侧大截肢或死亡(12.5% vs 5.6%;P<0.001)、再干预/截肢或死亡(19% vs 8.6%;P<0.001)均更高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Although endovascular therapy is often the first-line option for medically refractory intermittent claudication (IC) caused by aortofemoral disease, suprainguinal bypass is often performed. Although this will often be aortofemoral bypass (AoFB), axillofemoral bypass (AxFB) is still sometimes performed despite limited data evaluating its utility in the management of IC. Our goal was to assess the safety and durability of AxFB performed for IC. METHODS: The Vascular Quality Initiative (2009-2019) was queried for suprainguinal bypass performed for IC. Univariable and multivariable analyses were used to compare the perioperative and 1-year outcomes between AxFB and a comparison cohort of AoFB. RESULTS: We identified 3261 suprainguinal bypasses performed for IC: 436 AxFBs and 2825 AoFBs. The mean age was 61.4 ± 9.1 years, 58.8% of the patients were men, and 59.7% currently smoked. Patients undergoing AxFB, compared with AoFB, were more often older, male, never smokers and ambulated with assistance (P < .001 for all). They had more often had hypertension, diabetes, coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease, and end-stage renal disease and had more often undergone previous outflow peripheral endovascular interventions and previous inflow or outflow bypass. The AxFBs, compared with the AoFBs, were more often unifemoral (P < .05). Patients who had undergone AxFB, compared with AoFB, had had a shorter postoperative length of stay (median, 4 vs 6 days) and fewer perioperative pulmonary (3% vs 7.9%) and renal (5.5% vs 9.9%) complications but had required more perioperative ipsilateral major amputations (0.9% vs 0.04%; P < .05 for all). No significant differences were found in the incidence of perioperative myocardial infarction (2.8% vs 2.7%), stroke (0.7% vs 1.1%), or death (1.8% vs 1.7%). At 1 year, the Kaplan-Meier analysis demonstrated that the AxFB cohort, compared with the AoFB cohort, had had higher rates of death (7.3% vs 3.6%; P = .002), graft occlusion or death (14.3% vs 7.2%; P = .001), ipsilateral major amputation or death (12.5% vs 5.6%; P < .001), and reintervention, amputation, or death (19% vs 8.6%; P < .001). On multivariable analysis, AxFB was independently associated with an increased risk of 1-year reintervention, amputation, or death (hazard ratio, 1.6; 95% confidence interval, 1.03-2.4; P = .04). CONCLUSIONS: The results from the present retrospective analysis suggest that long-term complications were more frequent in patients who had undergone AxFB compared with AoFB, although patients treated with AxFB had had a greater risk with more comorbidities. Because AxFB was associated with significant perioperative morbidity, mortality, and long-term complications, serious consideration should be given before its use to treat IC.
引用
- Levin SR, Farber A, King EG, et al. Outcomes of axillofemoral bypass for intermittent claudication. J Vasc Surg. 2021. PMID: 34954271. doi:10.1016/j.jvs.2021.12.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。